Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iEVs for Lateral Epicondylitis
NCT07111325Phase 2Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of induced pluripotent stem cell-derived exosomes in Lateral Epicondylitis (LET) (4 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Visual Analogue Scale at 12 weeks, Patient-Rated Tennis Elbow Evaluation at 12 weeks and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
induced pluripotent stem cell-derived exosomes
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on NCT07111325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111325.